What’s Next? Five Things To Look Out For In November
Mylan-Upjohn’s Viatris Set To Emerge
Executive Summary
In November, Generics Bulletin will host its seventh annual Global Generics & Biosimilars Awards, while the long-awaited merger of Mylan and Pfizer’s Upjohn is set to complete and third-quarter financial results dominate the landscape.
You may also be interested in...
Divided FTC Okays Mylan-Upjohn Merger But Election Outcome Could Impede Future Deals
Commissioners vote 3-2 that Mylan and Pfizer’s Upjohn can combine after divesting seven products; dissenting votes focus on price fixing allegations as commissioners Chopra and Slaughter criticize majority for not addressing government’s case against Pfizer and Mylan. Former FTC attorneys note that if Biden wins the presidential election, he could nominate one of the dissenters to FTC chair and give more traction to their views.
FTC Narrowly Approves Mylan-Upjohn Merger As Dissenters Call For Change
Mylan’s proposed $12bn combination with Pfizer’s Upjohn unit is expected to close next month following a settlement agreement with the FTC, with a requirement to address competition concerns in ten markets. The FTC was however strongly divided on the deal, with dissenters labelling the directives of the Commission as “deeply flawed, favoring routine over rigor.”
Who’s Hired? Four Firms Focus On Finance
A flurry of financial appointments has been seen across the off-patent industry, involving major players Dr Reddy’s, Biocon, Mayne Pharma and Xbrane Biopharma.